ketamine hydrochloride süstelahus
panpharma laboratories - ketamiin - süstelahus - 50mg 1ml 10ml 25tk
zenalpha
vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psühhoeptikumid, uinutid ja rahustid - koerad - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.
minims oxybuprocaine hydrochloride silmatilgad, lahus
laboratoire chauvin s.a. - oksübuprokaiin - silmatilgad, lahus - 4mg 1ml 0.5ml 20tk
vitamin b6 pyridoxin hydrochloride süstelahus
ao biopharm - püridoksiin - süstelahus - 50mg 1ml 1ml 10tk
pyridoxine hydrochloride süstelahus
pat lubnyfarm - püridoksiin - süstelahus - 50mg 1ml 1ml 10tk
pyridoxine hydrochloride injection süstelahus
brooks laboratories limited - püridoksiin - süstelahus - 50mg 1ml 2ml 5tk
naloxone hydrochloride süstelahus eeltäidetud süstevahendis
kimball electronics, inc. - naloksoon - süstelahus eeltäidetud süstevahendis - 10mg 0.4ml 0.4ml 10tk
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
orladeyo
biocryst ireland limited - berotralstat dihydrochloride - angioödeem, pärilik - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.